Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Melanoma 8Lung Neoplasms 8Neoplasm Metastasis 6Colorectal Neoplasms 6Solid Tumours 5Neoplasms 5Breast Neoplasms 4Uveal Melanoma 3Thyroid Neoplasms 3Pancreatic Neoplasms 3Neurofibromatosis 1 3Colonic Neoplasms 3Thyroid Cancer, Papillary 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Adult Solid Neoplasm 2Thyroid Diseases 1Thymoma 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Renal Insufficiency 1Rectal Neoplasms 1Optic Nerve Glioma 1Non-small Cell Lung Cancer Metastatic 1Neurofibrosarcoma 1Neurofibroma, Plexiform 1Neuroblastoma 1Myelodysplastic-Myeloproliferative Diseases 1

Interventions

aldesleukin 26Sunitinib 25Interferon-alpha 21Everolimus 18Sorafenib 16Cyclophosphamide 16Filgrastim 13Bevacizumab 13Nivolumab 11Gemcitabine 11Interleukin-2 10Axitinib 10fludarabine phosphate 9Gene Expression Profiling 9temsirolimus 8Peripheral Blood Stem Cell Transplantation 8Doxorubicin 8pembrolizumab 7Radiotherapy 6Radiosurgery 6Polymerase Chain Reaction 6Ipilimumab 6Carboplatin 6sargramostim 5Ifosfamide 5Fluorouracil 5Erlotinib Hydrochloride 5Capecitabine 5Bortezomib 5atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Kidney Neoplasms × AZD 6244 × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡